Howard Homler
Internal Medicine · Carmichael, CANPI 1629039177
Payments from drug & device makers
What this record shows
Almost everything reported here is food and beverage — 99.9% of the total across 90 separate payments, which is the pattern of a clinician who attends manufacturer presentations rather than one with a consulting arrangement. It is spread thinly across 33 manufacturers, the largest accounting for just 18.7% — the pattern of someone who eats at a lot of different presentations. Reporting peaked in 2019 at $1,237 and has fallen 78.2% since, to $270 in 2025.
Across 90 payments — averaging $41.61 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Neurocrine Biosciences, Inc.$699
- Amarin Pharma, Inc.$333
- Novo Nordisk$260
- AstraZeneca$256
- Amgen$200
- Salix Pharmaceuticals, A Division Of Bausch Health US, LLC$193
- plus $2K from 27 others
What the payments were for
- Food & beverage$3,743100%
- Education$20%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Neurocrine Biosciences, Inc. | 6 | $699 |
| Amarin Pharma, Inc. | 8 | $333 |
| Novo Nordisk | 5 | $260 |
| AstraZeneca | 5 | $256 |
| Amgen | 7 | $200 |
| Salix Pharmaceuticals, A Division Of Bausch Health US, LLC | 4 | $193 |
| AbbVie(2 entities) | 10 | $169 |
| Radius Health, Inc. | 8 | $164 |
| Lilly USA, LLC | 5 | $157 |
| Daiichi Sankyo Inc. | 3 | $137 |
| Genentech USA, Inc. | 1 | $134 |
| Merck | 2 | $134 |
| Incyte Corporation | 1 | $125 |
| Regeneron Healthcare Solutions, Inc. | 1 | $120 |
| Beigene USA, Inc. | 1 | $112 |
| Abbott | 1 | $107 |
| Novartis | 1 | $88 |
| GSK | 2 | $42 |
| Pfizer | 2 | $34 |
| Hikma Pharmaceuticals USA | 2 | $33 |
| Eyevance Pharmaceuticals LLC | 2 | $33 |
| E.r. Squibb & Sons, L.L.C. | 2 | $27 |
| Boehringer Ingelheim | 1 | $25 |
| Medicure Pharma Inc. | 1 | $24 |
| Acadia Pharmaceuticals Inc | 1 | $19 |
| Teva Pharmaceuticals USA, Inc. | 1 | $18 |
| Takeda Pharmaceuticals U.S.A., Inc. | 1 | $17 |
| Jazz Pharmaceuticals Inc. | 1 | $16 |
| Boston Scientific | 1 | $15 |
| Johnson & Johnson | 1 | $15 |
| Kowa Pharmaceuticals America, Inc. | 1 | $14 |
| Alnylam Pharmaceuticals Inc. | 1 | $13 |
| Alfasigma USA, Inc. | 1 | $12 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
How this compares
$3,745 in reported general payments places this provider in the 85th percentile of 13,581 internal medicine providers in California.
Other internal medicine in Carmichael
- Andrew ChengSouth San Francisco$55.1M
- Tung NgoNewport Beach$4.9M
- Christian EversullStanford$2.9M
- Christian SandrockSacramento$2.1M
- Hatim HusainSan Diego$2M
- Teck LingPalo Alto$1.1M
- Hyong Kimla Jolla$1M
- Rohit Loombala Jolla$965K
- Fred CohenSan Francisco$929K
- Steven EdelmanSan Diego$863K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Identity: NPPES NPI Registry, July 2026.